iSono Health is reinventing breast cancer screening with ATUSA, a wearable automated 3D ultrasound device that captures full-volume breast images in under two minutes without radiation, compression, or specialized sonographer skill. Founded in 2015 by Maryam Ziaei (CEO) and Shadi Saberi (CTO), both PhD engineers from UC Berkeley, the company graduated from Y Combinator's W16 batch with a mission to close the screening gap for the 40 percent of women with dense breast tissue, for whom mammography misses up to half of cancers.
ATUSA is a portable cup-shaped device that fits around the breast and uses a rotating ultrasound transducer to capture a complete 3D volume scan automatically. The accompanying AI software analyzes the imaging data to flag suspicious regions for physician review, with deep learning models trained specifically on dense-tissue imaging. The device is designed for use in primary care clinics, OB-GYN offices, and global health settings where access to specialist radiology is limited. ATUSA received FDA 510(k) clearance, opening the U.S. market for adjunct breast screening.
iSono Health has raised approximately $13.5M across seed and Series A rounds, backed by SOSV, HAX, Joyance Partners, Social Impact Capital, Astia Fund, and Y Combinator. The Series A closed in March 2023 and supports commercial rollout, expanded clinical studies, and AI model refinement. The company partners with health systems and clinics to deploy ATUSA as a complement to mammography, particularly for younger women and those with dense breast tissue.